To intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast material-enhanced breast magnetic resonance (MR) imaging by using a prospective, multicenter double-blind, randomized protocol.
Institutional review board approval and patient informed consent were obtained. One hundred sixty-two women (mean age, 52.8 years 6 12.3 [standard deviation ]) enrolled at 17 sites in Europe and China between July 2007 and May 2009 underwent at least one breast MR imaging examination at 1.5 T by using three-dimensional spoiled gradient-echo sequences. Of these, 151 women received both contrast agents in randomized order in otherwise identical examinations separated by more than 2 but less than 7 days. Images, acquired at 2-minute or shorter intervals after contrast agent injection, were evaluated independently by three blinded radiologists unaffi liated with enrollment centers. Histopathologic confi rmation was available for all malignant lesions ( n = 144), while benign lesions were confi rmed either by using histopathologic examination ( n = 52) or by at least 12-month diagnostic follow-up ( n = 20) with mammography and/or ultrasonography. Determinations of malignant lesion detection rates and diagnostic performance (sensitivity, specifi city, accuracy, positive predictive value [PPV] , and negative predictive value [NPV] ) were performed and compared (McNemar and Wald tests). A full safety assessment was performed.
Results:
Signifi cant superiority for gadobenate dimeglumine was noted by readers 1, 2, and 3 for malignant lesion detection rate (91.7%, 93.1%, 94.4% vs 79.9%, 80.6%, 83.3%, respectively; P Յ .0003). Readers 1, 2, and 3 reported signifi cantly superior diagnostic performance (sensitivity, specifi city, and accuracy) for breast cancer detection with gadobenate dimeglumine (91.1%, 94.5%, 95.2% vs 81.2%, 82.6%, 84.6%; 99.0%, 98.2%, 96.9% vs 97.8%, 96.9%, 93.8%; 98.2%, 97.8%, 96.7% vs 96.1%, 95.4%, 92.8%, respectively; P Յ .0094) and significantly superior PPV (91.1%, 85.2%, 77.2% vs 80.7%, 75.5%, 60.9%, respectively; P Յ .0002) and NPV (99.0%, 99.4%, 99.4% vs 97.8%, 98.0%, 98.1%, respectively; P Յ .0003). No safety concerns were noted with either agent.
Conclusion:
Gadobenate dimeglumine is superior to gadopentetate dimeglumine for breast cancer diagnosis.
q RSNA, 2010 Clinical trial registration no. NCT00486473 ( http://www .clinicaltrials.gov/). Our aim was to intraindividually compare 0.1 mmol/kg doses of these agents for breast MR imaging by using a prospective, multicenter, double-blind design, with images evaluated individually by three independent, blinded readers. [ 17 ] ) has recently confi rmed that the highest sensitivity for breast cancer detection is achieved by using MR imaging. Any means to improve the diagnostic performance of MR imaging still further could greatly affect the initial approach to patient work-up and the subsequent treatment and outcome of patients with diagnosed disease and may also have an effect on screening guidelines.
Materials and Methods
To maximize the diagnostic information attainable, it is essential to optimize image acquisition to better depict and characterize nodules following contrast agent administration. Recently, two intraindividual crossover studies demonstrated improved diagnostic performance with the high relaxivity MR contrast agent gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) relative to the standard relaxivity agent gadopentetate dimeglumine (Magnevist; Bayer HealthCare, Berlin, Germany) when administered at equivalent doses of 0.1 mmol per kilogram of body weight ( 18, 19 ( 1 ) . In the United States, the overall breast cancer incidence rates have remained relatively stable since 2003, although screening programs and improved early cancer detection have led to a steady decrease in the incidence of invasive cancer and an increase in the incidence of in situ cancer ( 1 ) .
Of the techniques available for breast cancer detection and staging, magnetic resonance (MR) imaging is the most sensitive. However, despite superior diagnostic performance relative to conventional mammography and ultrasonography (US) ( 2-15 ), MR imaging is currently recommended by the American Cancer Society as a screening procedure for high-risk women only ( 16 ) . In looking
Implications for Patient Care
The NPV of breast MR imaging n was very close to 100% with both agents, indicating that the risk of overlooking malignant lesions with MR imaging is extremely low; these data confi rm that MR imaging is an accurate tool for screening women at high risk of breast cancer and highlight its value for staging breast cancer, determining the most appropriate treatment, and following up patients after breast cancer treatment.
Gadobenate dimeglumine should n be preferred over gadopentetate dimeglumine, because it provided signifi cantly improved diagnostic performance (greater sensitivity, specifi city, NPVs, and PPVs).
Advances in Knowledge
Three independent blinded readn ers reported signifi cantly better cancer detection rate with gadobenate dimeglumine than with gadopentetate dimeglumine when these agents were administered to the same patients at an equivalent dose of 0. 
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Contrast agent was administered intravenously by using a power injector in 158 (97.5%) women, at a rate of 2 mL/sec in 139 (85.8%) women, 1.8 mL/ sec in two (0.01%) women, and 1.5 mL/ sec in 17 (0.10%) women, or as a manual bolus in four (2.5%) women at a rate of 1-2 mL/sec for approximately 10 seconds, ensuring that the same rate was used for both examinations in each patient. Each contrast agent was administered at an identical dose of 0.1 mmol/kg (0.2 mL/kg) according to a randomization list and was followed by a 20-mL saline fl ush. The interval between examinations was longer than 48 hours in all patients to avoid any carryover effect but less than 7 days to ensure full comparability between examinations.
to group B ( n = 80) received the agents in reverse order ( Fig 1 ) .
MR Imaging
All procedures were performed at 1. 
Patients
One hundred sixty-two women with an abnormality at mammography or US (category 3, 4, or 5 for suspicion of malignancy according to the Breast Imaging Reporting and Data System classifi cation [ 20 ] ) who were highly likely to undergo biopsy or surgery were enrolled at 17 sites in Europe and China between July 2007 and May 2009. Patients were enrolled because of unclear diagnosis at mammography and/or US before histologic confi rmation ( n = 78), for cancer staging because of equivocal mammographic and/or US fi ndings before histologic confi rmation ( n = 59), for cancer staging after histologic confi rmation but before surgery ( n = 11), or for preoperative work-up of a lesion suspected of being malignant ( n = 14). No more than 18 women were enrolled at any site. Patients with congestive heart failure (New York Heart Association classifi cation IV) or a known allergy to either agent were ineligible. Patients were also ineligible if they had received or were scheduled to receive another contrast medium within 24 hours before or after either examination, any other investigational compound and/or medical device within 30 days before until 24 hours after administration of the second agent, or were scheduled to undergo any intervention between the two examinations. Finally, patients were ineligible if they were pregnant or lactating or had any medical condition or other circumstance (eg, metallic vascular stent, pacemaker, severe claustrophobia) that would decrease the chances of performing an adequate examination or which would preclude proximity to a strong magnetic fi eld.
The 162 eligible women (mean age, 52.8 years 6 12.3 [standard deviation]; range, 24-87 years) were randomized prospectively to two groups (groups A and B) for breast MR imaging. Patients randomized to group A ( n = 82) received gadobenate dimeglumine for the fi rst examination and gadopentetate dimeglumine for the second; patients randomized The false-positive rate (FPR) for malignant lesion detection (malignant lesions detected with MR imaging but not confi rmed at histologic examination) and the rate of cancer misdiagnosis (malignant lesions found at histologic examination that were diagnosed as benign with MR imaging) were determined for both contrast agents.
Comparison of lesion conspicuity, lesion border delineation, and diagnostic preference was performed by using the Wilcoxon signed rank test.
Interreader agreement in detecting or assessing lesion nature was determined by using generalized weighted k statistics and was classifi ed as excellent
All statistical tests were two sided at the P , .05 level of signifi cance and were performed by using dedicated software (SAS, version 8.2; SAS, Cary, NC).
Results
Group A comprised 82 women (mean age, 53.3 years 6 13.4; range, 24-87 years) and group B comprised 80 women (mean age, 52.3 years 6 11.0; range, 24-79 years) ( Fig 1 ) . There were no between-group differences in age ( P = .63), height ( P = .86), or race ( P = .36), although the subjects in group B were slightly heavier, with a mean weight of 69.0 kg 6 11.4 versus 65.2 kg 6 9.8 ( P = .03). All 162 subjects were evaluated for safety. Of these women, 91 (56.2%) were postmenopausal (24 had surgical menopause), seven (4.3%) were perimenopausal ( , 1 year without menses), and 64 (39.5%) were premenopausal. Fifty-one (31.5%) subjects had a familial history of breast cancer.
Eleven subjects discontinued after the fi rst examination (seven discontinued after the examination with gadobenate dimeglumine, four discontinued after the examination with gadopentetate second contrast agent. Events were classifi ed as serious or nonserious (mild, moderate, or severe). Event severity and its relationship to the study contrast agent (probable, possible, unrelated, or unknown) were assessed by the investigating radiologist.
Vital sign (blood pressure, heart rate) measurements and 12-lead electrocardiograms were obtained within 1 hour before and after the administration of each contrast agent.
Statistical Analysis
The study was powered to show a difference in sensitivity of approximately 15% between contrast agents for the diagnosis of malignant lesions. By using the McNemar test of equality of paired proportions (nQuery, version 6.01; Statistical Solutions, Cork, Ireland), and assuming 25% discordant pairs, that each subject will have one malignant lesion, and considering a 20% dropout rate, evaluation of 130 subjects was necessary for 90% of power in a two-sided test with an a level of .05.
Comparison of demographic characteristics between groups A and B was performed by using the Student t test for continuous variables and the x 2 test for categorical variables.
Determinations were performed of the cancer detection rate (number of malignant lesions at MR imaging divided by the number of malignant lesions at histologic examination) and of the diagnostic performance (sensitivity, specifi city, accuracy, positive predictive value [PPV], and negative predictive value [NPV] for the diagnosis of malignant lesions) of breast MR imaging at the regional level relative to truth-standard fi ndings. For the latter analysis, a region with at least one confi rmed malignant lesion was considered to be a true-positive fi nding, while a region without a malignant lesion (no lesion or a confi rmed benign lesion) was considered to be a true-negative fi nding. Technically inadequate MR images were considered false-negative, if the region had a malignant lesion at truth standard, or false-positive, if the region had no lesion or a benign lesion. Differences in sensitivity, specifi city, and accuracy were determined together with 95% confi dence
Image Evaluation
All images were evaluated independently by three radiologists (L. Martincich, M.F., C.M.Z., with 5-10 years of experience in breast MR imaging) who were unaffi liated with the study centers and were fully blinded to the contrast agent used in each examination, to all patient clinical and radiologic information, and to the results of all interpretations by on-site investigators.
Images were presented for review on a multimonitor imaging workstation (AquariusNet Viewer for Windows, version 4.4.1.4; TeraRecon, San Mateo, Calif). All routine image processing functions (eg, window and level, zoom, pan) were available. Two independent reading sessions (paired and unpaired assessments) were performed by each reader and are detailed in Appendix E1 (online).
Lesion Tracking (Adjudication)
A fourth independent radiologist (S.C., with 20 years of experience in breast imaging), who was unaffi liated with the study centers and was blinded to all clinical and radiologic information and to the fi ndings of the blinded readers, reviewed all on-site fi nal diagnosis (truth standard) data (patient profi les, original mammographic, US, and histopathologic and/or surgical reports). Histopathologic confi rmation was available for all malignant lesions ( n = 144). Benign lesions were confi rmed either with histopathologic examination ( n = 52) or with at least a 12-month diagnostic follow-up ( n = 20) with mammography and/or US. All truth-standard lesions were numbered, mapped, and characterized. Lesions identifi ed by each off-site blinded reader were matched against truth-standard lesions characterized by the adjudicator. Lobular carcinoma in situ (LCIS) was considered a malignant lesion, as it is usually a candidate for resection ( 21, 22 ) .
Safety Assessments
All subjects were monitored for adverse events from the time the informed consent was obtained until 24 hours after administration of the fi rst contrast agent, and then from 24 hours before until 24 hours after administration of the 
Cancer Detection Rate and FPRs (Lesion-Level Analysis)
A truth-standard diagnosis was available for 216 lesions in 136 (90.7%) of 150 patients available for paired assessment (144 malignant and 52 benign lesions confi rmed with histopathologic examination in 132 patients; 20 benign lesions confi rmed with follow-up in 10 patients [nota bene, fi ve subjects had histologically confi rmed malignant and benign lesions, six subjects had histologically confi rmed malignant lesions and benign lesions confi rmed with follow-up]). The 144 histologically confi rmed malignant lesions comprised 127 invasive dimeglumine) ( Fig 1 ) , while one further patient was excluded from effi cacy evaluation because of contrast agent extravasation during the first examination. Therefore, 157 subjects who received gadobenate dimeglumine and 155 who received gadopentetate dimeglumine were assessed. Overall, 150 evaluable subjects received both contrast agents. Truth-standard data were available for 153 subjects ( After adjudication, analysis of the cancer detection rate was performed for 142 of 148 subjects who received gadobenate dimeglumine and 143 of 147 subjects who received gadopentetate dimeglumine; blinded paired assessment was performed for 136 subjects who received both contrast agents ( Fig 1 ) . At the regional level, analysis was performed for 145 of 148 subjects who received gadobenate dimeglumine and 145 of 147 subjects who received gadopentetate dimeglumine; blinded paired assessment was performed for 138 subjects.
Technical Adequacy and Anatomic Coverage
The three readers considered almost all examinations with both contrast agents 
Overall Diagnostic Performance (Region-Level Analysis)
A total of 1530 breast regions were assessed (10 regions per patient; the misdiagnosed lesions were apparent. The FPR for malignant lesion detection was similar with the two contrast agents for readers 1 and 2 but was approximately twice as high with gadopentetate dimeglumine for reader 3 ( Note.-Data were based on paired analysis, which includes only lesions with a fi nal truth-standard diagnosis after adjudication. The P values were determined with the McNemar test and were P , .0001 for readers 1 and 2 and P = .0003 for reader 3.
* Numbers in parentheses were used to calculate the percentages on the basis of n = 144.
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respectively; P , .0001) with gadobenate dimeglumine for the detection of breast cancer ( Table 6 ) Note.-Analysis includes only lesions with a fi nal truth standard diagnosis after adjudication. Ellipses indicate that the percentages for differences, 95% CIs (where applicable), and P values apply to comparisons of gadobenate dimeglumine with gadopentetate dimeglumine for each reader. FN = false-negative fi ndings, FP = false-positive fi ndings, TN = true-negative fi ndings, TP = true-positive fi ndings.
* Numbers in parentheses were used to calculate the percentages. Sensitivity was calculated as TP/(TP + FN). Specifi city was calculated as TN/(TN + FP). Accuracy was calculated as (TP + TN)/ (TP + TN + FP + FN). PPV was calculated as TP/(TP + FP). NPV was calculated as TN/(TN + FN)
. † Numbers in parentheses are 95% CIs. Differences and 95% CIs were determined by using the paired binary approach. P values for differences were determined by using the McNemar test. ‡ P values for differences were determined by using the Wald test from generalized estimating equations.
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glumine in signifi cantly ( P Յ .0003) more patients for determinations of lesion conspicuity, lesion border delineation, and overall diagnostic preference ( Table 7 ) .
Safety
Eleven adverse reactions to gadopentetate dimeglumine were recorded in seven (4.3%) patients (four reports of nausea, two of dizziness, two of dysgeusia, and one each of vomiting, vertigo, and headache), while eight reactions to gadobenate dimeglumine were recorded in six (3.7%) patients (two of dizziness, two of vertigo, and one each obenate dimeglumine was noted by all readers for benign lesions and by readers 1 and 3 for malignant lesions ( Fig 3 ) . The mean SI increase with gadobenate dimeglumine relative to gadopentetate dimeglumine ranged between 13.22% (reader 2) and 25.59% (reader 3) for malignant lesions and between 19.27% (reader 1) and 37.63% (reader 3) for benign lesions. No meaningful differences were noted concerning the appearance of SI-time curves.
Matched-Pairs Assessments
Each reader preferred gadobenate dimeglumine over gadopentetate dime-60.9%, respectively; P Յ .0002) and NPV (99.0%, 99.4%, 99.4% vs 97.8%, 98.0%, 98.1%, respectively; P Յ .0003). Examples of the improved diagnostic performance with gadobenate dimeglumine are given in Figures 2 and E1 and E2 (online).
Quantitative Assessments
Differences in peak quantitative lesion SI enhancement were determined by readers 1, 2, and 3 for 115, 103, and 112 confi rmed malignant lesions and 30, 29, and 28 confi rmed benign lesions, respectively. Signifi cantly ( P , .0058) greater peak SI enhancement with gad- SI-time curve after gadopentetate dimeglumine administration was classifi ed as type III by only one reader; the other two readers classifi ed the curve as type II. All readers noted considerably greater SI enhancement after gadobenate dimeglumine administration, as evident from the SI-time curves and the maximum intensity projection reconstructions after (e) gadobenate dimeglumine and (f ) gadopentetate dimeglumine administration. Evaluation of images in matched pairs confi rmed unanimous reader preference for gadobenate dimeglumine for lesion conspicuity, border delineation, and overall diagnostic preference.
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the diagnostic yield of MR imaging, the focus of studies has been primarily on imaging hardware and improved protocol design ( 30-33 ) rather than on differences between MR contrast agents. In part, this refl ects the similar R1 relaxivity of conventional gadolinium agents (4.3-5.0 L · mmol 2 1 · sec 2 1 at 1.5 T [ 34 ] ) and, thus, minimal differences in peak lesion SI enhancement and dynamic contrast enhancement behavior when these contrast agents are administered at an equivalent dose. Gadobenate dimeglumine differs from gadopentetate dimeglumine and similar contrast agents in possessing roughly twofold higher R1 relaxivity in vivo owing to weak, transient interaction with serum albumin (34) (35) (36) (37) (38) . This translates into increased SI enhancement and improved diagnostic performance in breast MR imaging ( 18, 19, 39 ) and other MR applications (40) (41) (42) (43) (44) (45) (46) (47) (48) . The results of this multicenter, intraindividual crossover study confi rm those of earlier single-center ( 18, 19 ) and interindividual parallel group studies ( 39 ) in showing that the greater SI enhancement with gadobenate dimeglumine at 0.1 mmol/kg results in significantly ( P Յ .0003) greater breast cancer detection and signifi cantly ( P Յ .0094) better diagnostic performance relative to that achieved with gadopentetate dimeglumine at an equivalent dose. Notably, the improved diagnostic performance with gadobenate dimeglumine was observed for all lesion types, including noninvasive cancers whose accurate identifi cation has previously been considered a potential limitation of MR imaging ( 12,13 ). It is important to emphasize that the readers in this study were unaffi liated with the investigational centers, and they were blinded to all patient radiologic and clinical information and to the contrast agent used in each examination. Previous single-center studies to determine the diagnostic performance of breast MR imaging have utilized on-site readers in which the risk of unintentional interpretation bias is inevitably greater, potentially resulting in infl ated values for sensitivity, specifi city, and overall accuracy. The readers in our study were presented solely with the images from
Discussion
Multiple studies have shown that breast cancer detection is superior with MR imaging rather than with conventional imaging, both in breasts with known cancer ( 2-14,17 ) and in contralateral breasts (24) (25) (26) (27) (28) (29) . In looking to improve of dysgeusia, decreased blood pressure, increased heart rate, and an abnormal electrocardiogram). All adverse reactions were nonserious, were mild in intensity, and resolved spontaneously within 24 hours. There were no differences in vital sign measurements or electrocardiograms. NPV was noted with gadobenate dimeglumine by all readers ( P Յ .0003), indicating that the risk of overlooking malignant disease is signifi cantly lower with this contrast agent.
Concerning the widespread introduction of breast MR imaging into routine practice, this has been hampered by reports of low specifi city and high FPRs (56) (57) (58) . Whereas MR imaging cannot always help to distinguish cancerous from noncancerous abnormalities and while it is not uncommon for the morphologic-kinetic enhancement of benign lesions to simulate malignancy, in our study the cancer misdiagnosis rate was markedly lower with gadobenate dimeglumine for readers 1, 2, and 3 (2.6%, 4.0%, 3.5% for gadobenate dimeglumine vs 4.9%, 6.6%, 11.9% for gadopentetate dimeglumine). Concerning the number of false-positive results, this number was relatively low with both contrast agents for two readers but twice as high with gadopentetate dimeglumine (23.4% vs 12.7%) for the third reader. Although false-positive diagnoses leading to unnecessary biopsies are a concern, from a clinical perspective, the additional true-positive malignant lesions detected should outweigh the occasional misdiagnosis of benign lesions, particularly if patients are at high risk for breast cancer and if the falsepositive fi nding does not prompt the clinician to change the surgical treatment to wider local excision or mastectomy ( 59, 60 ) .
Our study was limited in that there is no comparison with mammography or US and no analysis according to lesion type.
Recently, the EVA trial showed that MR imaging alone provides signifi cantly improved cancer detection relative to mammography and US and that combined MR imaging and mammography provides no signifi cant benefi t over MR imaging alone in terms of cancer yield ( 17 ) . Although no information on the type of gadolinium chelate used in the EVA trial was provided, our results extend these fi ndings to show that the MR contrast agent used can markedly improve the diagnostic performance of breast MR imaging. Specifi cally, our each examination in randomized order, and all interpretations were made by using standard image interpretation tools.
Given the unreliability of SI-time curves for the confi dent characterization of lesion nature ( 22, 23, (49) (50) (51) , the better diagnostic performance with gadobenate dimeglumine can be ascribed to improved depiction of lesion morphologic features that are characteristic of either malignancy or benignancy. Features characteristic of invasive malignancy include an irregular shape; irregular, ill-defi ned, or spiculated margins; and internal inhomogeneous contrast distribution. On the other hand, the features of ductal cancers in situ include the large spectrum of nonmasslike enhancement (52) (53) (54) . It is likely that the greater SI enhancement with gadobenate dimeglumine enabled better depiction of malignant features, resulting in more true-positive determinations and fewer false-positive and false-negative determinations than with gadopentetate dimeglumine at an equivalent dose. Notably, vital tumor regions indicative of malignant neoangiogenesis are known to be associated with increased microvascular permeability to plasma proteins ( 55 ) . It is thus possible that gadobenate dimeglumine would prove benefi cial in better depicting regions of active tumor growth in which the level of plasma proteins is elevated. In matched-pair assessments of lesion conspicuity, border delineation and overall diagnostic preference, each reader preferred gadobenate dimeglumine in signifi cantly ( P Յ .0003) more patients than the reader did gadopentetate dimeglumine.
Of particular interest are the predictive values determined by the three readers. The PPV determinations indicate that a breast region with a positive fi nding determined with gadobenate dimeglumine is up to 91.1% likely to harbor malignant disease and that this percentage is signifi cantly ( P Յ .0002) higher than the likelihood determined with gadopentetate dimeglumine. In regard to NPV, this value was high ( . 97%) with both contrast agents, confi rming the value of MR imaging in general for breast cancer screening. Nevertheless, a higher 
